Otonomy Reports Positive Top-Line Results from Phase I/II Clinical Trial of OTO-413 in Patients with Hearing Loss

Investor presentation:


It’s a safety trial mainly, but they tested a bunch of efficacy endpoints as well- mostly various measures of speech understanding in noise. The drug addresses the fairly recently described condition of synaptopathy. It’s not supposed to move thresholds, but improve understanding.

Key points:

small numbers, no change in the placebo group, a number of participants who received the highest dosage showed ‘meaningful clinical improvement’.

It’s interesting to me as a proof of concept. It would be nice to see the full results.

Nice! Improving understanding in noise is huge. Can’t wait to see how it goes in the future.

1 Like